Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Drug Price Freeze Confirmed For Four Years In Latest Reforms

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.

You may also be interested in...



German Pharma Wants Inflation-Linked Deal To Replace Drug Price Freeze

With the German drug price freeze set to continue, the pharmaceutical industry wants to see at least an inflation-linked rise in prices and the abandonment of HTA for older products.

German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs

Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.

Germany Cuts Pharma Rebate Level While Keeping Price Freeze

German coalition negotiation proposals will see government slash the obligatory rebate for pharma companies while continuing the current prize freeze. But old products will be exempt from HTA.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel